This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Aralez Bio


Aralez Bio uses enzymes to make thousands of novel noncanonical amino acids (ncAAs) readily accessible for the first time at both lab and commercial scales via efficient, sustainable biomanufacturing. Our biocatalytic platform produces high-quality, chiral building blocks that enable drug developers to create the next generation of therapeutics to treat diseases previously considered undruggable. The diversity of ncAAs produced using enzymes are useful across all stages of drug discovery from screening to SAR. Additionally, the scalability of enzyme-based synthesis provides a reliable and economically viable path to clinical/commercial scale up. Noncanonical amino acids are found in blockbuster peptide drugs such as Semaglutide as well as in the latest generation of drug modalities such as macrocycles and antibody drug conjugates (ADCs). Aralez Bio makes unique, never-seen-before ncAAs and creates isomeric series of ncAAs that allow for fine-tuning of chemical properties.